Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Resverlogix Corp.
  6. News
  7. Summary
    RVX   CA76128M1086

RESVERLOGIX CORP.

(RVX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about RESVERLOGIX CORP.
01/18Resverlogix Starts Patient Enrollment and Dosing in Phase 2b Trial For "Promising" Cana..
MT
01/18Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial..
AQ
01/18Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial..
CI
2021RESVERLOGIX : The Future of Drug Development, CEO Clip Video
NE
2021Resverlogix Announces Corporate Update Webcast and Conference Call
AQ
2021RESVERLOGIX : Financial Statement Q3 2021
PU
2021RESVERLOGIX : Md&a q3 2021
PU
2021Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021Resverlogix Enters into a Cooperation Agreement with Supreme Council of Arab-African Ec..
MT
2021Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-Af..
AQ
2021Resverlogix in Active Talks With Morocco's Ministry of Health to Launch COVID-19 Clinic..
MT
2021Resverlogix In Active Discussions With The Kingdom of Morocco's Ministry of Health For ..
AQ
2021Resverlogix Corp. in Active Discussions with Kingdom of Morocco?s Ministry of Health fo..
CI
2021Resverlogix to Participate in Leading Scientific Conferences
AQ
2021RESVERLOGIX : Study demonstrates resverlogix's apabetalone treatment significantly improve..
AQ
More most relevant news
All news about RESVERLOGIX CORP.
01/18Resverlogix Starts Patient Enrollment and Dosing in Phase 2b Trial For "Promising" Cana..
MT
01/18Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial..
AQ
01/18Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial..
CI
2021RESVERLOGIX : The Future of Drug Development, CEO Clip Video
NE
2021Resverlogix Announces Corporate Update Webcast and Conference Call
AQ
2021RESVERLOGIX : Financial Statement Q3 2021
PU
2021RESVERLOGIX : Md&a q3 2021
PU
2021Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021Resverlogix Enters into a Cooperation Agreement with Supreme Council of Arab-African Ec..
MT
2021Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-Af..
AQ
More news
News in other languages on RESVERLOGIX CORP.
01/18Resverlogix annonce le début du recrutement et du dosage des patients pour un essai de ..
01/18Resverlogix annonce le début du recrutement et du dosage des patients pour un essai de ..
01/18Resverlogix commence le recrutement des patients et le dosage dans le cadre de l'essai ..
01/18Resverlogix annonce le début du recrutement des patients et du dosage dans un essai de ..
2021Resverlogix et Eversana s'associent pour soutenir la commercialisation initiale de l'ap..
2021Resverlogix conclut un accord de financement par obligations de 6 millions de dollars U..
2021Resverlogix affirme que l'apabétalone est une première médicale chez les patients attei..
2021Resverlogix affirme que le traitement à l'apabétalone prévient l'infection des cellules..
2021Resverlogix en hausse de 3 % grâce aux preuves publiées des effets bénéfiques de l'apab..
2021Resverlogix fait le point sur l'effet positif de l'apabétalone sur les patients hospita..
More news
Press releases
01/18Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial..
AQ
2021RESVERLOGIX : The Future of Drug Development, CEO Clip Video
NE
2021Resverlogix Announces Corporate Update Webcast and Conference Call
AQ
2021RESVERLOGIX : Financial Statement Q3 2021
PU
2021RESVERLOGIX : Md&a q3 2021
PU
More press releases
Upcoming event on RESVERLOGIX CORP.
03/30/22